Welcome to our dedicated page for RELMADA THERAPEUTICS SEC filings (Ticker: RLMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Relmada Therapeutics, Inc. uses SEC filings to document its clinical-stage biotechnology business, Nasdaq-listed common stock, governance, operating results, and capital structure. Its Form 8-K filings cover financial results, Regulation FD presentations, FDA feedback and NDV-01 clinical or regulatory disclosures, material agreements, executive employment arrangements, and equity financing activity.
Proxy filings address board matters, executive compensation, shareholder voting items, and related governance disclosures. Capital-structure records include common stock and pre-funded warrant disclosures associated with financing transactions.
Relmada Therapeutics entered into a private placement securities purchase agreement with institutional and accredited investors for approximately $160.0 million, selling 29,474,569 common shares at $4.75 and pre-funded warrants for 4,210,527 shares at $4.749 with a $0.001 exercise price. Closing is expected on March 11, 2026, and proceeds are earmarked for working capital and to advance research and development of its product candidates. Investors receive registration rights for resale and liquidated damages if registration timelines are missed.
The company also reported 12‑month interim Phase 2 NDV‑01 data in high‑risk non‑muscle invasive bladder cancer, showing a 12‑month complete response rate of 76% overall and 80% in the BCG‑unresponsive subgroup, with no progression to muscle‑invasive disease or radical cystectomies. These results support moving NDV‑01 into the Phase 3 RESCUE registrational program across both adjuvant intermediate‑risk and second‑line BCG‑unresponsive settings.
Relmada Therapeutics, Inc. received an updated ownership report showing a near-10% stake held by Squadron-affiliated funds and principals. Squadron Master Fund LP, together with Squadron Capital Management, LLC, William Blank, and Matthew Sesterhenn, report beneficial ownership of 7,395,510 shares of Common Stock.
This position consists of 6,700,000 common shares plus 695,510 shares issuable upon exercise of warrants held by Squadron Capital Management, LLC. Based on 73,333,622 shares outstanding as of November 10, 2025, plus these warrant shares, the group’s holdings represent approximately 9.99% of Relmada’s common stock.
The Squadron entities and individuals report shared voting and dispositive power over all 7,395,510 shares and no sole power. The investment adviser and its partners expressly disclaim beneficial ownership and state that the securities are held in the ordinary course of business, not for the purpose of changing or influencing control of Relmada.
Relmada Therapeutics, Inc. disclosed that investment manager Spruce Street Capital LP, together with Alex R. Rosen and Simon Basseyn, reported beneficial ownership of 4,086,181 shares of common stock, representing 5.57% of the company. This percentage is based on 73,333,622 shares outstanding as of November 10, 2025. The investors certify the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Relmada.
Relmada Therapeutics, Inc. is the subject of a Schedule 13G showing that Adage Capital Management, L.P. and related individuals beneficially own 4,270,000 shares of its common stock, representing 5.82% of the class. This percentage is based on 73,333,622 shares outstanding as of November 10, 2025.
The reporting persons have shared voting and dispositive power over all reported shares and no sole power. They state the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Relmada Therapeutics.
Janus Henderson Group plc filed a Schedule 13G reporting beneficial ownership of 7,439,415 shares of Relmada Therapeutics, Inc. common stock, representing 10.1% of the class. The shares are held across various managed portfolios of Janus Henderson’s asset management subsidiaries, which exercise investment and voting discretion.
Janus Henderson reports shared voting and shared dispositive power over all reported shares, with no sole voting or dispositive power. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Relmada Therapeutics.
Relmada Therapeutics, Inc. has updated its at-the-market stock sales program to offer up to $100,000,000 of common stock through Jefferies LLC as sales agent under an existing Open Market Sale Agreement.
The company states it has not previously sold any shares under this program and is amending the prior prospectus materials to reflect the higher aggregate amount. Relmada’s common stock trades on the Nasdaq Global Select Market under the symbol RLMD, and the last reported sale price was $3.91 per share on January 29, 2026. The company also notes it is no longer subject to the Form S-3 General Instruction I.B.6 limitations because the aggregate market value of its non-affiliate holdings was at least $75.0 million as of January 28, 2026.
Relmada Therapeutics CEO and director Sergio Traversa reported buying 27,500 shares of the company’s common stock in multiple open market transactions at a weighted average price of $4.12 per share, with individual purchase prices ranging from $4.10 to $4.12.
Following these purchases, he beneficially owns 1,300,000 common shares directly. Traversa was also granted 1,198,000 stock appreciation rights with a conversion price of $4.06, each linked to one share of common stock. These rights vest in 16 equal quarterly installments beginning on March 12, 2026 and expire on December 12, 2035, with 1,198,000 derivative securities shown as beneficially owned after the transaction.
Relmada Therapeutics, Inc.'s chief financial officer reported buying 11,665 shares of common stock on December 15, 2025 at $4.12 per share, bringing his directly held stake to 800,000 shares. In a separate transaction on December 12, 2025, he was granted 828,000 stock appreciation rights with a $4.06 exercise price, each linked to one share of common stock and expiring on December 12, 2035. These rights begin vesting on March 12, 2026 in 16 equal quarterly installments, providing additional long-term equity-based compensation tied to the company’s stock.
Relmada Therapeutics, Inc. reported that one of its officers with the title "CA and CO" received 828,000 stock appreciation rights12/12/2025$4.0603/12/202612/12/203516 equal quarterly installments828,000 derivative securities
Relmada Therapeutics director Fabiana Fedeli reported receiving a grant of 164,000 stock appreciation rights on December 12, 2025. These derivative securities relate to Relmada Therapeutics common stock and carry an exercise price of $4.06 per right. The award was reported as an acquisition transaction and is held with direct ownership.
The stock appreciation rights are scheduled to vest in 16 equal quarterly installments, commencing on March 12, 2026, providing a staged vesting profile over time. The instruments become exercisable starting March 12, 2026 and have an expiration date of December 12, 2035, giving a long-dated window in which they may be exercised.